-
Story
A partnership against epilepsy -
Press Release
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
-
Featured News
World Sight Day 2022: Raising awareness on the importance of eye health -
Press Release
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
-
Story
Sickle cell screening urged for newborns in Africa -
Press Release
Novartis announces partnership with the American Society of Hematology to fight sickle cell disease in Sub-Saharan Africa
-
Press Release
Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria
-
Press Release
Novartis and GSK announce collaboration to support scientific research into genetic diversity in Africa
-
Press Release
Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
-
Press Release
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
-
Press Release
Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients
-
Press Release
Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis